Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Provided By GlobeNewswire
Last update: Oct 16, 2024
MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the World Obesity and Weight Management Congress, taking place October 24-26, 2024, in Baltimore, Maryland.
0.5229
-0.01 (-2.12%)
Find more stocks in the Stock Screener
VERU Latest News and Analysis
20 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
20 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
